United Kingdom. The Medicines Control Agency has approved a novel oral agent for the treatment of glioma, a common form of brain tumour. The product is temozolomide (Temodal: Schering-Plough), an imidazotetrazine alkylating agent. Temozolomide was developed at Aston University under the auspices of the Cancer Research Campaign. The company has also applied for marketing approval for the use of temozolomide for the treatment of advanced malignant melanoma.
Reference: The Pharmaceutical Journal 262, p.42, 9 January 1999.